OncoMed Pharmaceuticals (OMED) has named John Lewicki as CEO, president, and a member of the board of directors effective immediately. Lewicki, who joined OncoMed in 2004 as senior vice president of research and development, was named the company's chief scientific officer in 2009, and then became executive vice president, research and development in 2016. He was named the company's president in January.
Oncomed Pharmaceuticals Inc
Equities
US68234X1028
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |